Compare Adaptive Biotechnologies Corp (ADPT) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Costco Wholesale Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Costco Wholesale Corporation trades at $942 (market cap $420.20B). The key difference: Costco Wholesale Corporation is far larger — about 126.2× Adaptive Biotechnologies Corp's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | COST | |
|---|---|---|
Market Cap | $3.33B | $420.20B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $1.09K |
52-Week Low | $10.24 | $849.63 |
Enterprise Value | $3.19B | $408.34B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Costco (COST) trades at $953.13, up 0.3% on the day, with a bearish technical signal but strong fundamentals including consistent revenue growth to $275.24B in 2025 and net income of $8.10B. Recent March sales surged 11.3% year-over-year, and the company announced a dividend of $1.47 payable in May 2026. Valuation metrics remain elevated with a P/E of 47.66, while analyst consensus is strongly bullish with a $1,110 price target.
The outlook is positive due to robust membership fee growth and expansion potential, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid despite a recent Q1 2026 miss, with Q2 2026 expected at $6.56 EPS. Institutional ownership trends show increased stakes, supporting confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
